BioCentury
ARTICLE | Clinical News

GSK reports more Votrient data

June 4, 2013 2:56 AM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) presented additional data from the Phase III AGO-OVAR16 trial evaluating Votrient pazopanib to treat ovarian, fallopian tube or primary peritoneal cancer at the American Society of Clinical Oncology meeting in Chicago. Maintenance treatment with once-daily Votrient for 24 months led to a median progression-free survival (PFS), the primary endpoint, of 17.9 months vs. 12.3 months for placebo (p=0.0021). GSK said there were insufficient events to estimate median overall survival (OS), a secondary endpoint, at the time of data cut-off. However, the pharma said the interim analysis showed no difference in survival between treatment groups. GSK disclosed in its 1Q13 earnings that Votrient met the primary PFS endpoint in the trial -- which enrolled 940 patients with cancer that did not progress after completing standard debulking surgery and first-line chemotherapy -- but the pharma declined to disclose details. ...